PL2771342T3 - Nowe pochodne puryny i ich zastosowanie w leczeniu chorób - Google Patents
Nowe pochodne puryny i ich zastosowanie w leczeniu choróbInfo
- Publication number
- PL2771342T3 PL2771342T3 PL12798854.1T PL12798854T PL2771342T3 PL 2771342 T3 PL2771342 T3 PL 2771342T3 PL 12798854 T PL12798854 T PL 12798854T PL 2771342 T3 PL2771342 T3 PL 2771342T3
- Authority
- PL
- Poland
- Prior art keywords
- disease
- treatment
- purine derivatives
- purine
- derivatives
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552746P | 2011-10-28 | 2011-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2771342T3 true PL2771342T3 (pl) | 2016-11-30 |
Family
ID=47326252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12798854.1T PL2771342T3 (pl) | 2011-10-28 | 2012-10-26 | Nowe pochodne puryny i ich zastosowanie w leczeniu chorób |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9334271B2 (pl) |
| EP (1) | EP2771342B1 (pl) |
| JP (1) | JP6059731B2 (pl) |
| KR (1) | KR20140090218A (pl) |
| CN (1) | CN104039790B (pl) |
| AP (1) | AP2014007601A0 (pl) |
| AU (1) | AU2012327954B2 (pl) |
| BR (1) | BR112014009890A2 (pl) |
| CA (1) | CA2853256C (pl) |
| CL (1) | CL2014001049A1 (pl) |
| CO (1) | CO6950473A2 (pl) |
| CU (1) | CU20140048A7 (pl) |
| EA (1) | EA023935B1 (pl) |
| ES (1) | ES2587533T3 (pl) |
| IL (1) | IL232256A0 (pl) |
| MX (1) | MX340452B (pl) |
| PH (1) | PH12014500912A1 (pl) |
| PL (1) | PL2771342T3 (pl) |
| PT (1) | PT2771342T (pl) |
| SG (1) | SG11201401716XA (pl) |
| TN (1) | TN2014000175A1 (pl) |
| WO (1) | WO2013061305A1 (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| US8987257B2 (en) | 2011-01-31 | 2015-03-24 | Novartis Ag | Heterocyclic derivatives |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| MA55696A (fr) | 2014-03-26 | 2022-02-23 | Astex Therapeutics Ltd | Combinaisons |
| JP6980385B2 (ja) | 2014-03-26 | 2021-12-15 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ |
| WO2015178955A1 (en) * | 2014-05-19 | 2015-11-26 | Eternity Bioscience Inc. | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors |
| CA2971687C (en) | 2014-12-30 | 2024-05-28 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| HRP20220012T1 (hr) | 2015-09-23 | 2022-04-01 | Janssen Pharmaceutica Nv | Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka |
| BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
| EP3241830A1 (de) | 2016-05-04 | 2017-11-08 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| MA45918A (fr) | 2016-08-15 | 2019-06-19 | Bayer Ag | Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides |
| CN113660946A (zh) * | 2019-02-06 | 2021-11-16 | 新索思股份有限公司 | Il-2缀合物及其使用方法 |
| CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| WO2020186220A1 (en) * | 2019-03-13 | 2020-09-17 | Immunophage Biomedical Co., Ltd. | Compounds as inhibitors of macrophage migration inhibitory factor |
| EP4161519A4 (en) * | 2020-06-03 | 2024-07-17 | Yumanity Therapeutics, Inc. | PURINES AND METHODS OF USE |
| US20250353851A1 (en) * | 2021-12-08 | 2025-11-20 | Kineta, Inc. | Purines and methods of their use |
| CN116283960A (zh) * | 2021-12-21 | 2023-06-23 | 上海安诺达生物科技有限公司 | 取代的稠杂环化合物及其制备方法与应用 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864145A (en) | 1959-06-02 | 1961-03-29 | Thomae Gmbh Dr K | Novel purines and a process for their manufacture |
| US3016378A (en) | 1959-07-01 | 1962-01-09 | Thomae Gmbh Dr K | Amino-substituted purine derivatives |
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4323581A (en) | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US4923986A (en) | 1987-03-09 | 1990-05-08 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance K-252 |
| US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
| WO1989007105A1 (fr) | 1988-02-04 | 1989-08-10 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| WO1993007153A1 (en) | 1991-10-10 | 1993-04-15 | Schering Corporation | 4'-(n-substituted-n-oxide)staurosporine derivatives |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| JPH07505124A (ja) | 1991-11-08 | 1995-06-08 | ザ ユニバーシティ オブ サザン カリフォルニア | ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物 |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5948898A (en) | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
| HUT70954A (en) | 1992-04-03 | 1995-11-28 | Upjohn Co | Bicyclic-heterocyclic amines containing nitrogen heteroatoms |
| US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
| US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
| FI950887A7 (fi) | 1992-08-31 | 1995-02-27 | Ludwig Inst For Cancer Res Ltd | MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt |
| US5674867A (en) | 1992-09-21 | 1997-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Indolocarbazole derivatives and therapeutic method for stimulating megakaicyocyte production |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| ATE195735T1 (de) | 1993-07-15 | 2000-09-15 | Minnesota Mining & Mfg | Imidazo (4,5-c)pyridin-4-amine |
| US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| JP3998261B2 (ja) | 1993-12-23 | 2007-10-24 | イーライ・リリー・アンド・カンパニー | プロテインキナーゼｃ阻害剤 |
| US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| WO1997007081A2 (en) | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| ATE321757T1 (de) | 1995-12-08 | 2006-04-15 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-chinolinonderivate als farnesyl protein transferase inhibitoren |
| KR100447918B1 (ko) | 1996-07-25 | 2005-09-28 | 동아제약주식회사 | 대장을포함한위장관보호작용을갖는플라본및플라바논화합물 |
| NZ333802A (en) | 1996-08-02 | 2001-09-28 | Genesense Technologies Inc | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| CA2294244A1 (en) | 1997-07-12 | 1999-01-21 | Cancer Research Campaign Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| IL139934A (en) | 1998-05-29 | 2007-10-31 | Sugen Inc | History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them |
| US20030083242A1 (en) | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
| PL203326B1 (pl) | 1999-06-25 | 2009-09-30 | Genentech Inc | Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała |
| US6806266B1 (en) | 1999-07-13 | 2004-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
| IL149034A0 (en) | 1999-11-05 | 2002-11-10 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| RS50444B (sr) | 2000-02-15 | 2010-03-02 | Sugen Inc. | Inhibitori 2-indolinon protein kinaze supstituisani pirolom |
| US6511984B2 (en) | 2000-03-30 | 2003-01-28 | Pfizer Inc. | Neuropeptide Y antagonists |
| AU2001253427B2 (en) | 2000-04-12 | 2007-02-08 | Genaera Corporation | A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group |
| JP4102185B2 (ja) | 2000-06-30 | 2008-06-18 | グラクソ グループ リミテッド | キナゾリンジトシル酸塩化合物 |
| PL211125B1 (pl) | 2000-09-11 | 2012-04-30 | Novartis Vaccines & Diagnostic | Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie |
| US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
| WO2002057423A2 (en) | 2001-01-16 | 2002-07-25 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| WO2002062826A1 (fr) | 2001-02-07 | 2002-08-15 | Vadim Viktorovich Novikov | Procede de fabrication des peptides |
| US20040186172A1 (en) | 2001-07-02 | 2004-09-23 | Houssam Ibrahim | Oxaliplatin active substance with a very low content of oxalic acid |
| KR100484504B1 (ko) | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물 |
| US20030134846A1 (en) | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
| EP1485082A4 (en) | 2002-02-19 | 2009-12-30 | Xenoport Inc | PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS |
| ATE447404T1 (de) | 2002-03-29 | 2009-11-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
| US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| WO2004060308A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
| WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| US20080058297A1 (en) * | 2003-05-29 | 2008-03-06 | Synta Pharmaceuticals Corp. | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
| CA2703138A1 (en) * | 2007-10-26 | 2009-04-30 | F. Hoffmann-La Roche Ag | Purine derivatives useful as pi3 kinase inhibitors |
| EP2244709A4 (en) | 2008-02-07 | 2012-02-29 | Synta Pharmaceuticals Corp | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS |
| WO2009146406A1 (en) * | 2008-05-30 | 2009-12-03 | Genentech, Inc. | Purine pi3k inhibitor compounds and methods of use |
| WO2010002954A1 (en) | 2008-07-02 | 2010-01-07 | Wyeth | (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| CA2740389A1 (en) | 2008-10-15 | 2010-05-20 | Gilead Sciences, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
| WO2010114494A1 (en) * | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders |
| AU2010254161A1 (en) | 2009-05-27 | 2011-11-10 | F. Hoffmann-La Roche Ag | Bicyclic pyrimidine PI3K inhibitor compounds selective for p110 delta, and methods of use |
| US9497928B2 (en) | 2009-06-08 | 2016-11-22 | Purdue Research Foundation | System for automating animal testing protocols |
| ES2432315T3 (es) | 2009-08-28 | 2013-12-02 | Takeda Pharmaceutical Company Limited | Compuestos de hexahidrooxazinopterina para su uso como inhibidores de mTOR |
| RU2607635C2 (ru) | 2009-11-12 | 2017-01-10 | Ф.Хоффманн-Ля Рош Аг | N-9-замещенные пуриновые соединения, композиции и способы применения |
| KR101447789B1 (ko) | 2009-11-12 | 2014-10-06 | 에프. 호프만-라 로슈 아게 | Ｎ-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법 |
| WO2011078795A1 (en) | 2009-12-21 | 2011-06-30 | S*Bio Pte Ltd | Bridged morpholino substituted purines |
| US8987257B2 (en) * | 2011-01-31 | 2015-03-24 | Novartis Ag | Heterocyclic derivatives |
| CN103650345A (zh) | 2011-07-22 | 2014-03-19 | 辉达公司 | 部件分析系统及方法 |
-
2012
- 2012-10-26 KR KR1020147013841A patent/KR20140090218A/ko not_active Abandoned
- 2012-10-26 AU AU2012327954A patent/AU2012327954B2/en not_active Ceased
- 2012-10-26 US US14/353,950 patent/US9334271B2/en not_active Expired - Fee Related
- 2012-10-26 JP JP2014537802A patent/JP6059731B2/ja not_active Expired - Fee Related
- 2012-10-26 CA CA2853256A patent/CA2853256C/en not_active Expired - Fee Related
- 2012-10-26 SG SG11201401716XA patent/SG11201401716XA/en unknown
- 2012-10-26 PL PL12798854.1T patent/PL2771342T3/pl unknown
- 2012-10-26 MX MX2014005132A patent/MX340452B/es active IP Right Grant
- 2012-10-26 CN CN201280064734.5A patent/CN104039790B/zh not_active Expired - Fee Related
- 2012-10-26 AP AP2014007601A patent/AP2014007601A0/xx unknown
- 2012-10-26 EP EP12798854.1A patent/EP2771342B1/en not_active Not-in-force
- 2012-10-26 PT PT127988541T patent/PT2771342T/pt unknown
- 2012-10-26 PH PH1/2014/500912A patent/PH12014500912A1/en unknown
- 2012-10-26 WO PCT/IB2012/055929 patent/WO2013061305A1/en not_active Ceased
- 2012-10-26 EA EA201490888A patent/EA023935B1/ru not_active IP Right Cessation
- 2012-10-26 ES ES12798854.1T patent/ES2587533T3/es active Active
- 2012-10-26 BR BR112014009890-5A patent/BR112014009890A2/pt not_active Application Discontinuation
-
2014
- 2014-04-24 TN TNP2014000175A patent/TN2014000175A1/en unknown
- 2014-04-24 CL CL2014001049A patent/CL2014001049A1/es unknown
- 2014-04-24 IL IL232256A patent/IL232256A0/en unknown
- 2014-04-28 CU CU2014000048A patent/CU20140048A7/es unknown
- 2014-04-29 CO CO14092008A patent/CO6950473A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013061305A1 (en) | 2013-05-02 |
| CN104039790B (zh) | 2016-04-13 |
| US20140336166A1 (en) | 2014-11-13 |
| TN2014000175A1 (en) | 2015-09-30 |
| MX2014005132A (es) | 2014-10-06 |
| JP2014530903A (ja) | 2014-11-20 |
| AU2012327954B2 (en) | 2015-11-26 |
| CU20140048A7 (es) | 2014-12-26 |
| US9334271B2 (en) | 2016-05-10 |
| MX340452B (es) | 2016-07-08 |
| IL232256A0 (en) | 2014-06-30 |
| NZ624366A (en) | 2015-12-24 |
| EA201490888A1 (ru) | 2014-09-30 |
| EP2771342B1 (en) | 2016-05-18 |
| EA023935B1 (ru) | 2016-07-29 |
| CA2853256C (en) | 2019-05-14 |
| CA2853256A1 (en) | 2013-05-02 |
| CO6950473A2 (es) | 2014-05-20 |
| AP2014007601A0 (en) | 2014-04-30 |
| CL2014001049A1 (es) | 2014-10-24 |
| AU2012327954A1 (en) | 2014-06-19 |
| JP6059731B2 (ja) | 2017-01-11 |
| CN104039790A (zh) | 2014-09-10 |
| ES2587533T3 (es) | 2016-10-25 |
| PH12014500912A1 (en) | 2014-06-09 |
| SG11201401716XA (en) | 2014-05-29 |
| BR112014009890A2 (pt) | 2020-10-27 |
| PT2771342T (pt) | 2016-08-17 |
| KR20140090218A (ko) | 2014-07-16 |
| EP2771342A1 (en) | 2014-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2771342T3 (pl) | Nowe pochodne puryny i ich zastosowanie w leczeniu chorób | |
| IL242610A0 (en) | History of pyrazolopyrrolidine and their use in the treatment of diseases | |
| IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
| IL232046A (en) | Furein derivatives for the treatment of viral infections | |
| IL221874A (en) | History of pyrimidine and their use in the treatment of respiratory diseases such as copd | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| IL227689A0 (en) | The history of aza-indole, their preparation and their use in the treatment of diseases | |
| IL228860A0 (en) | 2'-substituted nucleoside deriv atives and methods of use thereof for the treatment of viral diseases | |
| SG2014014450A (en) | Pyrrolopyrimidine and purine derivatives | |
| SMT201800064T1 (it) | Derivati di pirrolopirimidina per l'uso del trattamento di infezioni virali | |
| GB201120993D0 (en) | Novel compounds and their use in therapy | |
| PT3004108T (pt) | Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças | |
| PL3004112T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby | |
| EP2841064A4 (en) | USE OF N-ACETYLCYSTEINE AMIDE IN THE TREATMENT OF DISEASES AND INJURIES | |
| IL229381B (en) | Brilacitidine and its results for use in the treatment of mucositis | |
| PL2683826T3 (pl) | Zastosowanie aptamerów w terapii i/lub diagnostyce chorób autoimmunologicznych | |
| EP2740728A4 (en) | URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES | |
| GB201222455D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease | |
| ZA201500547B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| PL2729469T3 (pl) | Pochodne orwinolu i tewinolu użyteczne w leczeniu uzależnienia od narkotyków i alkoholu | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| IL233080A0 (en) | Bisarylsulfonamides used to treat inflammation and cancer | |
| PT2670769T (pt) | R2r1/2 em diagnóstico e terapêutica | |
| ZA201503266B (en) | Pyidone derivatives and uses thereof in the treatment of tuberculosis |